Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epratuzumab in Waldenstrom's Macroglobulinemia
NCT00113802Phase 2Terminated
- Sponsor
- Gilead Sciences
- Start
- Aug 2004
- Primary completion
- Dec 2006
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of epratuzumab in Waldenström's macroglobulinemia (WM), sponsored by Gilead Sciences. Primary endpoint: Serum measurements of IgM. Started Aug 2004; status: terminated.
02
Drugs
epratuzumab
03
Conditions
Waldenström's macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT00113802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00113802.